Charles Schwab
KROS icon

Charles Schwab’s Keros Therapeutics KROS Stock Holding History

Charles Schwab’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.7M Sell
158,712
-21,240
-12% -$237K ﹤0.01% 2839
2026
Q1 		$1.99M Sell
179,952
-6,827
-4% -$105K ﹤0.01% 2724
2025
Q4 		$3.8M Sell
186,779
-105,227
-36% -$1.85M ﹤0.01% 2560
2025
Q3 		$4.62M Buy
292,006
+8,603
+3% +$127K ﹤0.01% 2478
2025
Q2 		$3.78M Buy
283,403
+41,480
+17% +$560K ﹤0.01% 2448
2025
Q1 		$2.47M Sell
241,923
-37,759
-14% -$438K ﹤0.01% 2545
2024
Q4 		$4.43M Buy
279,682
+19,562
+8% +$1.02M ﹤0.01% 2386
2024
Q3 		$15.1M Buy
260,120
+32,492
+14% +$1.6M ﹤0.01% 1842
2024
Q2 		$10.4M Buy
227,628
+19,870
+10% +$1.07M ﹤0.01% 2031
2024
Q1 		$13.8M Buy
207,758
+26,180
+14% +$1.55M ﹤0.01% 1821
2023
Q4 		$7.22M Buy
181,578
+4,625
+3% +$145K ﹤0.01% 2157
2023
Q3 		$5.64M Buy
176,953
+29,168
+20% +$1.09M ﹤0.01% 2196
2023
Q2 		$5.94M Buy
147,785
+15,017
+11% +$658K ﹤0.01% 2167
2023
Q1 		$5.67M Sell
132,768
-584
-0.4% -$29.5K ﹤0.01% 2143
2022
Q4 		$6.4M Buy
133,352
+11,236
+9% +$525K ﹤0.01% 2081
2022
Q3 		$4.59M Buy
122,116
+19,941
+20% +$691K ﹤0.01% 2257
2022
Q2 		$2.82M Buy
102,175
+1,435
+1% +$63K ﹤0.01% 2443
2022
Q1 		$5.48M Buy
100,740
+2,404
+2% +$123K ﹤0.01% 2233
2021
Q4 		$5.75M Sell
98,336
-208
-0.2% -$10.4K ﹤0.01% 2280
2021
Q3 		$3.9M Buy
98,544
+19,960
+25% +$710K ﹤0.01% 2481
2021
Q2 		$3.34M Buy
78,584
+20,274
+35% +$1.1M ﹤0.01% 2550
2021
Q1 		$3.59M Buy
58,310
+2,577
+5% +$163K ﹤0.01% 2453
2020
Q4 		$3.93M Buy
55,733
+11,884
+27% +$749K ﹤0.01% 2338
2020
Q3 		$1.69M Buy
43,849
+442
+1% +$17.5K ﹤0.01% 2549
2020
Q2 		$1.63M Buy
+43,407
New +$1.34M ﹤0.01% 2486

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Charles Schwab's KROS Position: Q2 2026 in Review

Charles Schwab reduced its Keros Therapeutics (KROS) stake by 12% in Q2 2026, selling an estimated $237K and leaving 158,712 shares worth $1.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2839.

Charles Schwab first reported a position in KROS in Q2 2020 and has held it in 25 quarters since. The position peaked at $15.1M in Q3 2024. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Charles Schwab held 158,712 shares of Keros Therapeutics worth $1.7M as of Q2 2026.
  • Charles Schwab sold 21,240 Keros Therapeutics shares in Q2 2026, an estimated $237K.
  • Keros Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2839 holding.
  • Charles Schwab first reported a position in Keros Therapeutics in Q2 2020 and has held it in 25 quarters since.
  • Charles Schwab's Keros Therapeutics position peaked at $15.1M in Q3 2024.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.